18P Targeting MET-expressing NSCLC with a VNAR-based theranostic agent

Non-small cell lung cancer (NSCLC) comprises 85% of lung cancer cases and is the leading cause of cancer death in the U.S. Many NSCLC patients have genomic alterations that can be selectively targeted by molecular therapies. The MET receptor has key roles in cell proliferation and wound healing, and is altered in 3-4% and amplified in 3-6% of patients. While two tyrosine kinase inhibitors are approved for such patients, resistance inevitably develops. Novel treatment options for resistant patients are urgently needed.